AVITA Medical, Inc.
corporate_fare Company Profile
AVITA Medical, Inc. (NASDAQ:RCEL) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 24 items for RCEL at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-16, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 13 rated 8 or above. Recent SEC coverage for RCEL spans 10-Q, 8-K, 424B5, DEF 14A.
Recent high-impact activity:
- Cohealyx I Hits Primary Endpoint: Grafts Ready in Median 11 Days
- AVITA 10-Q Details Q3: Revenue $26.1M, Net Loss Narrowed to $6.2M, Going Concern Gone
- AVITA Q3 Revenue Up 53% to $26.1M; Guidance Raised, Going Concern Removed
- Q3 Revenue Jumps 53% to $26.1M, Guidance Raised, Going Concern Warning Lifted
- PermeaDerm Cuts Wound-Coverage Costs 70% vs Allograft in Pivotal Study
Financial Snapshot
Short Interest & Short Volume
6.12 days to coverFINRA reported short interest of 2,807,032 shares in RCEL as of the October 30, 2026 settlement, a 1.0% decrease from the prior period — about 6.1 days to cover at its recent average daily volume. On November 20, 2026, 48.8% of RCEL volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for RCEL, detected from its recent SEC filings · based on capital-structure filings through 2026-06-05.
Warrant Share Registration · Exercise Price Below Market
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →